Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Equity Average (2018 - 2025)

10x Genomics' Equity Average history spans 8 years, with the latest figure at $790.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 10.36% year-over-year to $790.7 million; the TTM value through Dec 2025 reached $790.7 million, up 10.36%, while the annual FY2025 figure was $753.2 million, 3.81% up from the prior year.
  • Equity Average for Q4 2025 was $790.7 million at 10x Genomics, up from $779.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $812.1 million in Q1 2022 and bottomed at $708.5 million in Q1 2025.
  • The 5-year median for Equity Average is $774.2 million (2023), against an average of $765.9 million.
  • The largest annual shift saw Equity Average surged 92.05% in 2021 before it dropped 9.58% in 2024.
  • A 5-year view of Equity Average shows it stood at $808.9 million in 2021, then dropped by 2.24% to $790.8 million in 2022, then dropped by 6.02% to $743.1 million in 2023, then decreased by 3.59% to $716.5 million in 2024, then increased by 10.36% to $790.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Equity Average are $790.7 million (Q4 2025), $779.2 million (Q3 2025), and $740.1 million (Q2 2025).